S&P 500 7,718.60 −0.38%
Nasdaq 26,506.99 −0.29%
S&P/TSX 36,513.80 −0.33%
Apple 319.97 −2.51%
Nvidia 230.36 +0.84%
Microsoft 499.70 −2.04%
Shopify 200.76 −0.10%
Royal Bank 291.48 −0.30%
CAD/USD 0.7231 −0.29%
CLOSED · 17:45 ET
Market ClerkRecap
Sun Sep 6 · markets closed2 signals today321 insider buys this week · $404MCIRO short report next: Sep 15The week ahead

HUMA

Humacyte, Inc.
NASDAQ · HEALTH CARE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
0.61
+0.01 +1.51%
USD · close Sep 4
MKT CAP $168.1MP/E DIV YIELD FCF YIELD -58.05%REV TTM $2.1M +159.3%NET INCOME −$96.7MNET CASH $43.6M52W 0.55 – 2.48NEXT EARNINGS Nov 12SEC XBRL · TTM TO Invalid Date

Financials

SEC XBRL · 32 PERIODS · WHOLE USD

By quarter

PeriodRevenueYoYGross marginOperating incomeNet incomeYoYEPSOp. cash flowCapexFree cash flowFiled
Q2 2026 · Jun 30$406K+34.9%-203.2%−$27M−$36.8M-0.16−$22.1M$104K−$22.2MAug 12
Q1 2026 · Mar 31$495K−4.3%-311.7%−$28.9M−$17.6M−145.0%-0.09−$25.1M$175K−$25.3MAug 12
Q4 2025 · Dec 31derived$467K-1844.8%−$30.8M−$24.8M-0.15−$26.1M$39K−$26.2MMar 27
Q3 2025 · Sep 30$753K65.5%−$24.4M−$17.5M-0.11−$23.9M$49K−$24MNov 12
Q2 2025 · Jun 30$301K29.2%−$29.7M−$37.7M-0.24−$26.4M$568K−$27MAug 12
Q1 2025 · Mar 31$517K71.6%−$23.2M$39.1M0.28−$28.6M$228K−$28.8MAug 12
Q4 2024 · Dec 31derived$0−$28.1M−$20.9M-0.16−$26.6M$63K−$26.6MMar 27
Q3 2024 · Sep 30$0−$30.2M−$39.2M-0.33−$22.9M$934K−$23.8MNov 12
Q2 2024 · Jun 30$0−$29.5M−$56.7M-0.48−$21.3M$184K−$21.5MNov 12
Q1 2024 · Mar 31$0−$26.6M−$31.9M-0.29−$27.3M$391K−$27.7MNov 12
Q4 2023 · Dec 31derived−$26.2M−$25.1M-0.24−$19.1M$150K−$19.2MMar 31
Q3 2023 · Sep 30−$24.6M−$26M-0.25−$13M$493K−$13.5MNov 8

By fiscal year

YearRevenueGross marginOperating incomeNet incomeNet marginEPSOp. cash flowCapexFree cash flowBuybacksDividends paid
FY2025 · to Dec 31$2M-376.1%−$108.1M−$40.8M-2003.6%-0.26−$105M$884K−$105.9M
FY2024 · to Dec 31$0−$114.4M−$148.7M-1.26−$98.1M$1.6M−$99.7M
FY2023 · to Dec 31−$100M−$110.8M-1.07−$73.3M$2.3M−$75.6M
FY2022 · to Dec 31−$84.6M−$12M-0.12−$71.1M$1M−$72.2M
FY2021 · to Dec 31−$81.2M−$26.5M-0.66−$81.2M$220K−$81.4M
FY2020 · to Dec 31−$64.6M−$66.5M-11.54−$55.6M$318K−$55.9M

Every number comes from Humacyte, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.

Watch HUMA. Know when insiders buy.
One email the day a filing lands. Free.